IRVING, TX–(Marketwire – October 25, 2010) – VHA Inc., the national health care network, has been named the 38th best place to work in health care by Modern Healthcare magazine. VHA is one of only 16 companies that have been ranked within the top 100 for three consecutive years and one of only six Texas-based health care-related companies to be included in this list. 

The magazine compiled this year’s list using information collected from thousands of health care workers at more than 300 health care companies nationwide, including hospitals, suppliers and service companies. Modern Healthcare asked a series of detailed questions related to:

• Leadership and planning
• Culture and communications
• Quality of working environment
• Training and development
• Compensation and benefits

VHA has 852 employees in Irving and an additional 662 employees throughout its 16 regional offices nationwide. VHA’s employee base includes 160 nurses, pharmacists and doctors, as well as many others who have worked in various roles in hospitals and in the health care industry.

About VHA
VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves 1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 38th best place to work in health care in 2010.

MAYNARD, MA–(Marketwire – October 25, 2010) –  Healthcare organizations are moving steadily toward electronic health record (EHR) adoption to improve patient care but, at the same time, are aware of downtime’s potential to erode EHR’s benefits, according to a Stratus Technologies–ITIC survey.

More than 70 percent of healthcare organizations surveyed have either implemented on-premise EHR systems or plan to. The number rises to 81 percent when outsource EHR providers are factored in. While only 6 percent of respondents are in the process of deploying an EHR system now, 35 percent plan to launch an on-premise system within the next year and 37 percent within the next 20 months.

“The survey results show that the majority of healthcare organizations clearly recognize how electronic health records can reduce overhead expenses and improve patient care,” said Laura DiDio, principal at ITIC. “They also understand that those benefits are contingent on maximum uptime, and where downtime would have the most serious effect.”

Uptime’s importance is clear in responses to questions about disruptions to patient care and important administrative processes. Only 11 percent said that inability to access EHR files would cause minor disruptions; 64 percent said there would be notable disruptions, mainly administrative; processing insurance claims and scheduling patient appointments were the most frequently cited at 67 and 53 percent. However, nearly half the respondents — 49 percent — said EHR system disruptions can increase the potential for patient data recording errors and 32 percent said it could cause errors in prescribing medications.

Despite the broad awareness of uptime’s importance, almost 20 percent of respondents were still unsure how inaccessible health records would affect administration and patient care.

“It’s heartening to see that most healthcare IT professionals understand their uptime needs, though we still need to be concerned about the 20 percent that doesn’t seem to grasp the issue, or have yet to begin an EHR evaluation or implementation,” said Nelson Hsu, senior director, Avance product line. “Uptime isn’t a ‘nice to have’ in medical applications. If a healthcare organization can’t see where interrupted access to patient medical records affects care, then they don’t understand why they need reliable hardware and software infrastructures that provide continuous uptime. Without that, their EHR projects — on premise or outsourced — lead to business disruption and the potential for compromised patient care.”

To see the full survey results, please visit: http://www.stratus.com/~/media/Stratus/Files/About/PressReleases/2010/20101025-ppt.ppt.

Also, Hsu will speak on the role of high uptime technology in EHR applications at the Healthcare IT Solutions Exchange conference on Oct. 26 at the Doubletree Hotel, 5400 Computer Drive, Westborough, Mass. His session, “It’s Not Meaningful If It’s Not Available,” will examine:

• how electronic health records are transforming the role of IT in healthcare;
• why server availability needs greater attention; and
• how to address the cost barrier. 

Case studies will demonstrate how providers met their ultimate goal of patient-centered care that in improves quality, affordability and outcomes for patients.

About Stratus Technologies
Stratus delivers the best uptime in the industry for the applications its customers depend on most for their success. With its resilient hardware and software products, monitored and managed with proactive service, Stratus helps to save lives and to protect the business and reputations of companies, institutions, and governments the world over. To learn more about worry-free computing, visit www.stratus.com.

© 2010 Stratus Technologies Bermuda Ltd. All rights reserved.

Stratus is a registered trademark of Stratus Technologies Bermuda Ltd. The Stratus Technologies logo is a trademark of Stratus Technologies Bermuda Ltd. All other marks are the property of their respective owners.

Click here to see all recent news from this company

SEATTLE, WA–(Marketwire – October 25, 2010) – Is there customer service in healthcare? When it comes to the billing process, many would say ‘no.’ As more patients deal with the burden of bill payments, healthcare providers are being challenged with maintaining patient relationships through improved communication, while increasing revenue during a sometimes difficult billing process. Most healthcare institutions regularly deal with a handful of insurance companies, but as a greater portion of financial responsibility for medical services moves toward patients, few are well-equipped to manage the payment process for literally thousands of individual consumers.

In this complimentary Webinar, Gregory VandenBosch, president at MedDirect, and Dr. George Gellert, MD, on behalf of Varolii Corporation, will share how the right conversation can inform patients about their healthcare expenses and increase payments more easily. They will also explain how effective revenue cycle management, helps healthcare organizations be more patient-centric and cost-effective at the same time. The session will also share real-world examples of how MedDirect and Varolii are revolutionizing the way providers and patients communicate.

WHEN: Wednesday, Oct. 27, 2:00 – 2:30 p.m. ET / 11:00 – 11:30 a.m. PT

WHAT: A complimentary Webinar highlighting how MedDirect helps patients manage their health expenses to resolve more accounts and improve patient satisfaction. The Webinar will help attendees discover:

• Why patients are reluctant to pay (it’s not what you think)  
• How healthcare providers can improve account resolution and improve patient satisfaction simultaneously
• Why the key findings from FierceHealthcare’s “Revenue Cycle Management 2010 Survey” matter

WHO: Gregory VandenBosch, president at MedDirect, helps leading healthcare providers increase patient-pay revenue and offload the retail revenue cycle process. Prior to co-founding MedDirect in 2000, VandenBosch worked in the banking industry and later joined ES Financial, Inc. He is a graduate of Hope College with a degree in Economics.

WHO: Dr. George Gellert, MD, is a physician epidemiologist and executive with 20 years of experience in health information and communication. Dr. Gellert is the former Chief Medical Officer and EVP for HCORP Inc. and Senior VP of Strategic Alliances at WebMD.

REGISTER: https://www.varolii.com/go/2010/rcmwebinar

BETHESDA, MD–(Marketwire – October 25, 2010) –  GetWellNetwork, Inc. today announced that All Children’s Hospital, a premiere children’s hospital in St. Petersburg, Florida, is giving each of its young patients access to an interactive bedside TV system that will not only entertain them, but educate and encourage them to take an active role in their health recovery. All Children’s Hospital is using GetWellNetwork’s pediatric solution called GetWell Town™ to provide its patients and families with the tools they need to become knowledgeable and engaged in their health care. 

Key features of GetWell Town are the clinical tools that help nurses and doctors deliver better patient-centered care. For instance, important messages about prescribed medications can be sent to patients even while they’re enjoying a movie or playing a game. The GetWell Town system can be programmed to interrupt entertainment content with actionable messages from their caregivers. In this way, although GetWell Town entertains its patients with superior internet browsing capabilities, e-mail, games and movies, it is always running clinical applications in the background that lead to better patient outcomes. 

“Using the bedside TV as a mechanism to engage young patients in their health care is a smart approach because we know kids will turn it on as soon as they’re in their rooms. We’re particularly impressed with the unique, kid-friendly design that really takes into account how today’s kids learn and absorb information,” said David Gardner, director of eHealth, All Children’s Hospital. “GetWellNetwork has worked with us every step of the way to ensure a smooth transition to our new facility; they’ve been a great partner.”

All Children’s is also leveraging GetWell Town in other areas of the hospital in addition to patient rooms. For children who come to the hospital for periodic blood transfusions or dialysis treatment for kidneys, the hospital has set up GetWell Town in treatment rooms to help make that time productive yet, fun. 

“The new hospital building is a tremendous expression of All Children’s dedication to the young patients and families they serve and we are honored to be a part of this,” said Shannon O’Neil, MSW, Director of Pediatrics, GetWellNetwork, Inc. “As children become better informed about their health, we believe better patient outcomes will result — which is why this partnership is so important.”

About GetWell Town
GetWell Town was developed in collaboration with GetWellNetwork’s National Children’s Hospital Task Force, comprised of 15 pediatric facilities across the U.S. as well as direct input from pediatric patients and their families. GetWell Town is designed to complement the kid-friendly spaces that children’s hospitals have worked hard to create and features exclusive content in partnership with KidsHealth® from Nemours.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

NEW ORLEANS, LA–(Marketwire – October 25, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) today announced plans with Kodak to deploy a new version of the MMRPro system (www.mmrprovideos.com) operating through a proprietary customized interface on the new KODAK Scan Station Pro 550 at Booth 1709 at the Medical Group Management Association (MGMA) Annual Conference. MMRPro (www.mmrpro.com) is supported by Kodak’s transactional scanning solution(s) to help physician offices and other small practices get a firm handle on converting patient billing, forms and medical charts into digital, easily managed and accessed files. The new KODAK Scan Station Pro 550 incorporates the power of KODAK Capture Pro Software to enhance direct connection to MMRPro Software, MMRGlobal’s secure, web-based document management and imaging solution. This enables easy capture and access to paper-based patient documents and charts with the utmost security — extremely important to healthcare professionals and their patients.

“The MMRPro software solution directly addresses the document imaging and management needs of small medical offices, group practices, surgery centers and small hospitals that rely heavily on using transactions-based processes and forms, including patient billing, prescription data, and medical charts,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “Using MMRPro today makes it easier for physicians to ultimately transition to a full-blown certified EMR system. This helps doctors qualify for stimulus dollars from the government and, additionally, from MMR’s proprietary stimulus program which can reward physicians with payments that could be far in excess of the government’s stimulus program.”

MMRPro also includes an e-prescribing module and an integrated patient portal, enabling patients to have timely access to their personal health information through MyMedicalRecords’ secure personal health records technology (www.mymedicalrecords.com). Patients can quickly and conveniently upload their health information to an MMR account in real time using any Internet-connected device.

“Meaningful use of electronic health records requires doctors to make personal health information available to their patients through a personal health record or patient portal by 2014. We believe that our patented product offering will exceed HIPAA requirements and is more user-friendly than any other PHR available today,” added Lorsch.

The transactional KODAK Scan Station Pro 550 features a customized solution using the capture and output capabilities found in KODAK Capture Pro Software, including barcodes, OCR, MICR and others. The new scanner incorporates an intuitive GUI touch panel allowing users to work seamlessly with the MMRPro Software, enabling the user to scan patient-related healthcare documents directly into MMRPro with the push of a single button. The MMRPro Software also allows updates for patient files via fax, e-mail or telephone messages, through secure, staff-based permissions.

“The solution with MMR is an example of how Kodak works with its network of Independent Software Vendor partners to create strategic, specific applications that do more at the point of capture,” said Brian Bagan, Director, Business Development, Document Imaging, United States and Canada, Kodak’s Business Solutions and Services Group. “Medical offices and other industries can use transactional scanning solutions to help automate their internal business processes, as well as improve the information sharing practices across offices.”

KODAK Products are backed by KODAK Service and Support, which is made up of more than 3,000 professionals reaching more than 120 countries. It is a leading multi-vendor integrated services provider, delivering consulting, installation, maintenance and support services for the commercial printing, graphic communications, document imaging, data storage, and retail industries. KODAK Service and Support professionals are uniquely qualified to provide services that control costs, maximize productivity, and minimize business risk.

About MMRGlobal, Inc.

MMRGlobal, Inc. (OTCBB: MMRF), through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (MMR), provides secure and easy-to-use online Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. MMRGlobal’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” “help” and “continue,” or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, its relationship with Kodak, government regulation and changes in healthcare initiatives, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – October 25, 2010) –  Crystal Research Associates, LLC announced today it has issued an Executive Informational Overview® (EIO®) on Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC). The full 64-page report can be found at www.crystalra.com.

Radient Pharmaceuticals Corporation (“Radient” or “the Company”) together with its wholly-owned subsidiary AMDL Diagnostics Inc. (ADI), is an in vitro (IVD) company commercializing Onko-Sure® (formerly DR-70®) — a non-invasive, IVD test kit that detects and monitors up to 19 types of cancer. Onko-Sure® helps physicians answer important clinical questions related to early disease detection and progression in order ultimately to improve patient outcomes and survival. The distinctive feature of Radient’s Onko-Sure® blood test is that it measures the accumulation of specific breakdown products in serum (blood) called fibrin and fibrinogen degradation products (FDPs). Research has found that FDP levels rise dramatically as cancer progresses. A potentially life-saving IVD cancer test, Onko-Sure® is currently cleared to monitor colorectal cancer (CRC) treatment/recurrence in the U.S.; to detect and monitor lung cancer in Canada; for use as a general cancer marker in Australia, Europe, India, Taiwan, and Vietnam; and for use in CRC patients in South Korea. Radient is working to obtain additional regulatory clearances for indications in the U.S. and abroad. Radient’s subsidiary, ADI, operates research and development and quality control laboratories and an ISO 13485:2003-certified manufacturing facility for Onko-Sure® production.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Crystal Research Associates, LLC:
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small- and mid-cap companies. Crystal Research Associates’ unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company’s product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of sixty-one thousand U.S. dollars and four hundred thousand, four-year warrants for its services in creating this report, for updates, and for printing costs.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

SAN CLEMENTE, CA–(Marketwire – October 25, 2010) –  Micro Identification Technologies, Inc. (OTCBB: MMTC) (MIT) announces that on October 27, 2010 at 1:00 PM (PDT) it will conduct a Webinar on the operation of the MIT 1000 Rapid Microbial Identification System. The objective of the Webinar is to demonstrate the speed and operational simplicity of performing bacteria identification (ID) tests using the MIT 1000 System and to give a brief education on the non-biological light scattering technology that is used to obtain an ID. The Webinar will be conducted by MIT’s Chief Technical Officer, Dr. David Haavig. Attendees may register for the Event at https://www3.gotomeeting.com/register/183951526. 

Michael Brennan, MIT’s Chairman and CEO, stated that “Based on feedback from current users and investors regarding our last Webinar, MIT plans to provide periodic Webinars to update the Company’s business and product achievements.” Mr. Brennan further stated, “We are certain the attendees at our upcoming Webinar will be impressed with both the technology and simplicity of use of our System.” 

About Micro Identification Technologies:

MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-identification.com

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT has performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

BRAMPTON, ONTARIO–(Marketwire – 25 oct. 2010) – En vue d’élargir sa gamme de produits médicaux inédits sur le plan technologique pour la réparation de l’aorte par technique endovasculaire, la société Medtronic, Inc. (NYSE:MDT), a annoncé aujourd’hui le lancement au Canada du système Captivia(MC) pour la pose du greffon endoprothèse thoracique Valian(R), un traitement minimalement effractif des anévrismes et d’autres lésions de l’aorte thoracique. Le système de pose Captivia est offert à l’échelle internationale depuis l’automne 2009.

Le système de pose Captivia comporte un mécanisme de saisie des pointes rehaussant le contrôle du greffon endoprothèse thoracique Valiant lors de son déploiement, ainsi qu’un enduit hydrophile appliqué sur le greffon pour faciliter l’accès à l’artère iliaque et la pose de l’endoprothèse par le biais du système vasculaire des patients. Le nouveau système Captivia Valiant permet aux médecins de traiter facilement et avec précision un vaste éventail d’anatomies à l’aide d’un greffon endoprothèse ultraconfortable pour ainsi atteindre des résultats cliniques optimaux. Le système de greffon endoprothèse thoracique Valiant et le système de pose Captivia sont tous deux en phase de recherche aux États-Unis, alors que leur utilisation est restreinte aux essais cliniques approuvés par la Food and Drug Administration.

Le docteur François Dagenais, chirurgien cardiaque à l’Institut universitaire de cardiologie et de pneumologie de Québec, a effectué 17 implantations du greffon endoprothèse thoracique Valiant à l’aide du système de pose Captivia. Le docteur Dagenais est un chef de file de renommée mondiale en réparation endovasculaire thoracique; il a été un pionnier de ce traitement non effractif au Canada.

“Le système de pose Captivia de l’endogreffon thoracique Valiant permet un déploiement précis”, a expliqué le docteur Dagenais. “Particulièrement dans les limites d’un débit cardiaque élevé et d’un arc aortique angulé, le système Captivia minimise l’effet de manche à air et le déploiement asymétrique occasionnel associé à ce type d’intervention. Un tel mécanisme de dégagement contrôlé peut réduire le détachement embolique en réduisant la manipulation de l’arc et en prévenant le recouvrement par inadvertance de sa ramification. De plus, l’endogreffon Valiant du système Captivia est recouvert d’un enduit hydrophile facilitant son insertion dans l’artère iliaque serrée ou sinueuse.”

Indiqué pour le traitement de diverses lésions de l’aorte thoracique, le greffon endoprothèse thoracique Valiant s’est imposé comme le système minimalement effractif de choix pour la réparation de l’aorte thoracique par technique endovasculaire à l’extérieur des États-Unis. Après quatre années d’expérience clinique, plus de 15 000 patients ont ainsi reçu un greffon endoprothèse thoracique Valiant à l’échelle mondiale. 

“Compte tenu de l’adoption et de l’usage de plus en plus répandus de notre greffon endoprothèse thoracique Valiant, le système de pose Captivia constitue une autre amélioration procurant aux médecins un outil d’accès et de pose exceptionnellement simple, en plus de la précision et du contrôle lors du déploiement”, a déclaré M. Tony Semedo, vice-président et directeur général des Innovations endovasculaires, une unité intégrée au groupe des produits cardiovasculaires de Medtronic. “Lorsqu’on l’adjoint au greffon endoprothèse thoracique Valiant, qui se distingue toujours par sa grande conformité, le nouveau système élargit les possibilités de traitement endovasculaire pour inclure davantage de patients atteints de maladies complexes de l’aorte.”

À titre de pionnière de la technique endovasculaire pour les réparations de l’aorte, Medtronic est en tête de l’industrie des greffons endoprothèses depuis les années 90. Plus de 175 000 patients ont été traités à l’aide de ses dispositifs. La société propose la plus vaste gamme de greffons endoprothèses. De ceux-ci, mentionnons les greffons endoprothèses abdominaux et thoraciques Talent(R) offerts aux États-Unis, ainsi que les greffons abdominaux Endurant(R) et thoraciques Valiant(R) à l’extérieur des États-Unis.

Medtronic a comme mission de faire évoluer le traitement des maladies cardiovasculaires en collaboration avec les grands cliniciens, chercheurs et scientifiques du monde entier.

Au sujet de Medtronic

Medtronic, Inc. (www.medtronic.com), dont le siège social se trouve à Minneapolis, est le chef de file mondial de la technologie médicale visant à soulager la douleur, rétablir la santé et prolonger la vie de millions de gens, à l’échelle planétaire.

Au sujet de Medtronic du Canada Ltée 

Medtronic du Canada Ltée vend, entretien et distribue les produits de Medtronic au Canada : des instruments médicaux pour le traitement des maladies cardiaques et vasculaires et du diabète, pour la chirurgie de la colonne vertébrale, la neurochirurgie ainsi que pour la chirurgie oto-rhino-laryngologique. Medtronic du Canada, dont le siège social se trouve à Brampton, en Ontario, emploie quelque 420 Canadiens répartis dans son centre d’opérations de Mississauga, ses bureaux régionaux de Vancouver et Montréal. Elle exploite également une usine de mise au point et de fabrication de cathéters d’ablation pour la fibrillation auriculaire (FA) – Medtronic CryoCath – dans la région métropolitaine de Montréal.

Toutes les déclarations sur les résultats financiers anticipés sont assujetties à des risques et à des incertitudes, tels qu’ils sont énoncés dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission (Commission des valeurs mobilières des États-Unis). Les résultats réels pourraient différer sensiblement des résultats anticipés.

BRAMPTON, ONTARIO–(Marketwire – Oct. 25, 2010) – Adding to its market-leading portfolio of innovative medical technology for endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE:MDT), announced today the Canadian launch of the Captivia(TM) Delivery System for the Valiant(R) Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta. The Captivia Delivery System has been available internationally since the fall of 2009 and was approved by Health Canada on August 3, 2010.

The Captivia Delivery System features tip capture for enhanced control of the Valiant Thoracic Stent Graft during deployment and a hydrophilic coating applied to the graft cover to facilitate iliac access and delivery through patients’ vasculature. The new Valiant Captivia system enables physicians to treat a wide range of anatomies with a highly conformable stent graft, with accuracy and ease of delivery to achieve optimal clinical results. Both the Valiant Thoracic Stent Graft and Captivia Delivery System are investigational in the United States, where their use is limited to clinical trials approved by the U.S. Food and Drug Administration.

Dr. Francois Dagenais, cardiac surgeon at the Institut universitaire de cardiologie et de pneumologie de Québec in Quebec City, has performed 17 Valiant Thoracic Stent Graft implantations with the Captivia Delivery System. Dr. Dagenais is a global thought leader on thoracic endovascular repair and has pioneered this non-invasive treatment in Canada.

“The Captivia delivery system for the Valiant thoracic endograft allows for precise deployment, explained Dr. Dagenais,” Especially within the high cardiac output and angulated aortic arch the Captivia system minimizes the “windsock effect” and the asymmetric deployment occasionally encountered in this procedure. Such a controlled release mechanism may reduce embolic dislodgement by reducing arch manipulation and avoid inadvertent arch branch coverage. In addition, the Captivia Valiant endograft is covered with a hydrophilic coating facilitating insertion of the endograft in tight or tortuous iliac anatomy.”

Indicated for the treatment of a variety of thoracic aortic lesions, the Valiant Thoracic Stent Graft has emerged as the minimally invasive “system of choice” for thoracic endovascular aortic repair (TEVAR) outside the United States. In four years of clinical experience, more than 15,000 patients worldwide have received the Valiant Thoracic Stent Graft. 

“Given the widespread acceptance and growing use of our Valiant Thoracic Stent Graft, the Captivia Delivery System represents an enhancement that provides physicians with outstanding ease of access and delivery, as well as deployment accuracy and control,” said Tony Semedo, vice president and general manager of Endovascular Innovations, part of the CardioVascular business at Medtronic. “Combined with the Valiant Thoracic Stent Graft, which retains its hallmark attribute of conformability, the new system will expand endovascular treatment to more patients with complex aortic disease.”

A pioneer of EVAR, Medtronic has been an innovator and leader in the stent graft industry since the 1990s, with more than 175,000 patients treated with its devices. The company offers the broadest portfolio of stent grafts. Among these are the Talent(R) Abdominal and Thoracic Stent Grafts in the United States, as well as the Endurant(R) Abdominal and the Valiant(R) Thoracic Stent Grafts outside the United States.

Medtronic is committed to advancing the treatment of cardiovascular disease through collaboration with leading clinicians, researchers and scientists worldwide.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

About Medtronic of Canada Ltd. 

Medtronic of Canada sells, services and distributes Medtronic products in Canada: medical devices used in cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs over 420 Canadians, it is headquartered in Brampton, Ontario, has regional offices in Vancouver and Montreal and an atrial fibrillation (AF) ablation catheter manufacturing facility – Medtronic CryoCath – in the Montreal metropolitan area.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

LUND, SWEDEN and LEIDEN, THE NETHERLANDS–(Marketwire – October 25, 2010) –  NeuroVive Pharmaceutical and to-BBB, the Dutch drug brain delivery company, are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies.

NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative cyclosporin-based pharmaceuticals for the treatment of traumatic brain injuries (TBI) and other neurological diseases. The Company’s first product NeuroSTAT®, is a novel, cremophor-free, cyclosporin-A lipid emulsion.

“The collaboration with to-BBB opens up the possibility of treating brain disorders beyond TBI. There is a tremendous unmet medical need in treating patients with acute neurodegeneration such as stroke, cardiac-arrest-induced brain damage and spinal cord injuries, where one can expect the blood-brain barrier (BBB) to significantly prevent drug penetration to the central nervous system (CNS)”, says Dr Eskil Elmér, CSO of NeuroVive.

Pieter Gaillard, CSO of to-BBB, adds: “The BBB is indeed a significant obstacle in the treatment of CNS disorders. to-BBB’s proprietary G-Technology^® can safely enhance drug delivery to the brain and we are excited to address this with NeuroVive’s cyclosporin-based pharmaceuticals”.

“Currently there are no approved pharmacological or cellular primary neuroprotective treatments for stroke and spinal cord injuries. Consequently, the need to develop treatment for acute degenerative disorders has never been greater than it is today. The deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke”, says Mikael Brönnegård, CEO of NeuroVive.

“We are very pleased to collaborate with NeuroVive,” says Willem van Weperen, CEO of to-BBB. We are convinced that synergies in research and clinical platforms as well as business and commercial strategies between to-BBB and NeuroVive will result in a very strong partnership that will benefit patients with these devastating CNS diseases”.

NeuroVive is funding the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.

About NeuroVive

NeuroVive Pharmaceutical AB is a Swedish drug development company. NeuroVive’s primary mission is to develop drugs which protect nerve cells. The company is currently conducting clinical trials with NeuroSTAT®. In addition to introducing NeuroSTAT® as the first cyclophilin-D-inhibiting mitochondrial protectant, NeuroVive is researching and developing variants of cyclophilin-inhibiting cyclosporins and new ways of transporting these drugs across the blood-brain barrier to the central nervous system. NeuroVive Pharmaceutical AB (publ) shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses and offers an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

About to-BBB

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

LOUISVILLE, KY–(Marketwire – October 24, 2010) –  ZirMed^®, a leading national provider of revenue cycle management solutions, today announced several significant company milestones.

This month, ZirMed processed its 750 millionth healthcare transaction. The company currently processes over 20 million monthly transactions that include patient payments, claims, remittances and eligibility verifications.

“We now process as many transactions in a month as we did in all of 2004,” said Jerry Merritt, president and chief executive officer of ZirMed Inc. “Our substantial organic growth is self-funded, not inflated by acquisitions. We have achieved growth through our partner relationships and integration of our solution into practice management and EMR systems.”

Over the last five years, ZirMed’s revenue has grown at a Compound Annual Growth Rate (CAGR) of 39%.

To help manage and accelerate ZirMed’s growth, the company recently added two new senior executives.

Kevin Weinstein joins ZirMed as Vice President of Marketing and will oversee industry relations, messaging and new opportunity generation as well as managing the company’s brand. He was previously Vice President of Marketing and Sales Operations at Allscripts. Mr. Weinstein also worked as a management consultant with Oliver Wyman and earlier oversaw the investment process for an early stage venture capital fund. Mr. Weinstein earned a Master of Business Administration from Northwestern University’s Kellogg School of Management and a Bachelor of Arts in English from Colgate University.

Kraig Brown joins ZirMed as the Vice President of Sales and will lead sales execution for the company. Mr. Brown comes to the company from PGi, a web, video conferencing and document delivery company, where he was Senior Vice President of Sales. While at PGi, Mr. Brown oversaw inside and web based sales, building significant industry partner relationships with companies such as Cisco Webex, Adobe, and Microsoft. Prior to joining PGi, Mr. Brown was Senior Vice President of Sales at Xpediate Consulting, a high-growth private company focused on healthcare compliance. Kraig Brown received his Bachelor of Science in Education at the University of Georgia and his Master of Arts at David Lipscomb University.

Showcasing at MGMA Annual Conference:

ZirMed will be showcasing its solutions October 24-27 at the MGMA Annual Conference, at the Ernest N. Morial Convention Center in New Orleans. ZirMed will be demonstrating its revenue cycle management solutions in Exhibit Booth #838. For more information about ZirMed, visit the company’s MGMA exhibit or visit www.zirmed.com.

About ZirMed:
ZirMed is a nationally recognized leader in delivering revenue cycle management solutions to healthcare providers. ZirMed enables healthcare providers to leverage the power of technology to cure administrative burdens and increase cash flow. ZirMed solutions include eligibility verification, credit/debit card processing, check processing, claims management, coding compliancy and reimbursement management, electronic remittance advice, patient statements, patient e-commerce solutions, provider credentialing, and lock box services. ZirMed solutions are designed to complement provider workflow and to provide innovative, creative and flexible solutions for healthcare’s most pressing administrative challenges. For more information about ZirMed, visit www.zirmed.com.

SUN VALLEY, CA–(Marketwire – October 22, 2010) –  XTend Medical (PINKSHEETS: XMDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, has secured the BioHarp patents as the agreement reached through mediation stated. The company released the following statement:

“XTend’s patent counsel, Knobbe, Martens, Olsen, & Bear, LLC, has successfully been able to secure the transfers of the patents associated with the BioHarp to XTend Medical. Now that the company has secured these patents, it can now move quickly to begin the commercialization of the BioHarp Medical device. The company has been in contact with several manufacturers interested in working closely with XTend to produce the BioHarp device. In addition, XTend continues to receive interest from numerous global distributors looking to bring the BioHarp into various countries for implementation into their healthcare programs wherein the BioHarp could play a large role in their future healthcare plans. In addition, veterinarian distributors in the U.S. and Europe feel the BioHarp could prove to be a valuable tool in pet care and have expressed a keen interest in working with XTend to sell and distribute the BioHarp. As the company progresses forward, exploring all of the opportunities presented for the BioHarp should assist the company in reaching its full potential in 2011 and beyond.”

About XTend Medical

XTend Medical is a company that specializes in the sales, manufacturing and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact them at [email protected] or visit their website at www.bioharpunius.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

MANCHESTER, UNITED KINGDOM–(Marketwire – Oct. 22, 2010) – More than half of British adults are classed as overweight so it’s no surprise that there’s a large and growing market for slimming pills and supplements, but new research has revealed that many of them don’t work.

With many pills boasting attractive results that range from pills which can bind body fat to prevent the body from absorbing it or pills that claim to speed up the metabolism, it’s no surprise that those who want to lose weight are tempted by the large variety of pills on offer.

As concerns over the products mount, experts are warning consumers not to be taken in by the claims found on many of the products. With misleading buzz words such as ‘certified medical device’ or ‘clinically proven’ it’s not hard to see why so many overweight people purchase the pills.

For those who are worried about their weight The Hospital Group provide a top class service in state-of-the-art facilities.

The Hospital Group is the UK’s biggest provider of weight loss surgery, including gastric bands, gastric bypasses and gastric balloons which can give you a healthier lifestyle.

David Ross, Chief Executive of The Hospital Group said: “The majority of slimming pills do not give long lasting or dramatic results and leave those who are battling with their weight feeling down.

“Many people will have struggled with their weight for years and as a result feel self conscious and have low self esteem. At The Hospital Group we can offer specialist surgeons who have maximum experience in the field of bariatric surgery.

“Whilst it is by no means a quick fix or easy option it can give long lasting results which can dramatically change a person’s life and restore their confidence.

“Those who come to The Hospital Group, can be assured of a dedicated, professional service, with astounding success rates and a limited waiting time. This latest news is just another reason to seek an effective weight loss solution with The Hospital Group.”

BARRIE, ONTARIO–(Marketwire – Oct. 21, 2010) – Ontario-based Barrie Physiotherapy was purchased by leading Canadian physiotherapy company PT Health in June 2009. Since the acquisition, Barrie Physiotherapy has completed extensive physical renovations, fee restructuring and managerial changes to make it more consistent with other PT Health physiotherapy clinics.

Barrie Physiotherapy has the distinction of being the area’s only Ontario Health Insurance Plan (OHIP) licensed physiotherapy clinic. Instead of waiting several weeks to receive care through the local hospital, individuals insured by OHIP can obtain medical attention at Barrie Physiotherapy within days. This allows the clinic to address patients’ needs much sooner—an important advantage, given the positive impact of early intervention. Ontario health insurance coverage is available primarily to individuals who are Canadian citizens, permanent residents, landed immigrants and valid work permit holders whose principle home is in Ontario and who meet certain physical presence requirements. 

While Barrie Physiotherapy caters to OHIP patients, people who do not have this publically-funded insurance can also take advantage of the clinic’s services at very reasonable costs. Barrie Physiotherapy provides assistance in a wide range of areas, including injuries from sports and automobile accidents; post fracture, stroke and surgical rehabilitation; and chronic pain from arthritis, fibromyalgia, sprains, strains, and back and neck ailments. The clinic also assists clients with Workplace Safety and Insurance Board (WSIB) claims, massage therapy, braces, lumbar supports, pillows, Transcutaneous Nerve Stimulation (TNS) devices and compression stockings. In the future, it will be expanding its offerings to include the services of a naturopath. 

Barrie Physiotherapy operates under the direction of physiotherapist Paul Love. A graduate of Ben Gurion University of Negev, Israel, Love has practiced physiotherapy since 1992. While in Israel, he was head of the physiotherapy department at Poriyah Hospital. He became a registered physiotherapist in Ontario in 2002. His professional experience in Canada includes working in retirement homes and long term care facilities, as well as setting up and managing Midland Physiotherapy for six and a half years. Love’s experience also encompasses the management of Barrie Physiotherapy, stroke rehabilitation and pulmonary physiotherapy. In addition, he has completed numerous courses in evidence-based physiotherapy for various orthopaedic conditions. Love is a skilled professional who is dedicated to providing high-quality services to Barrie Physiotherapy’s clients. “I believe in client-centered care and practice with an open mind and ear to ensure that our clients are getting the best care and attention possible,” Love said.

The addition of Barrie Physiotherapy to PT Health’s extensive network of clinics represents a major benefit to the public. The development will enable individuals who previously found physiotherapy prohibitively expensive to avail themselves of these services. It will also help those who previously paid for private-only services to reduce their health care costs while still receiving quality care under the attention of registered and experienced physiotherapists, kinesiologists and massage therapists.

Barrie Physiotherapy is conveniently located at 125 Bell Farm Road in Barrie, Ontario. For more information about the area’s only OHIP-funded physiotherapy clinic or PT Health, please contact Paul Love at (705) 725-1980 or visit www.PTHealth.ca.

About PT Health

Established in 1995, Ontario-based PT Health is an extensive network of physiotherapist-owned clinics located all throughout Canada. It has distinguished itself as one of the fastest-growing health care physiotherapy companies in the country. PT Health operates more than 90 physical therapy clinics across Canada and provides services to nearly 200 Canadian nursing homes. PT Health’s clinics are grounded in the principles of integrity, accountability and trust while delivering services in physiotherapy, occupational therapy, chiropody, sports medicine, athletic therapy, massage therapy and other areas. PT Health is committed to providing high-quality, progressive therapy to benefit their patients.

NEW YORK, NY–(Marketwire – October 21, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions to the medical community announced today the formation of the New York Health Information Network as a collaboration with Thrasys, Inc. a provider of next-generation health information technology and solutions. The New York Health Information Network (NYHIN) will be the first of many regional health information networks to be deployed by MedLink and Thrasys under a Connected Healthcare initiative launched by the two companies earlier this year. Connected Healthcare and regional health information networks will enable communities of physicians, patients, service centers, and health plans to coordinate care, manage costs, increase revenues, improve outcomes and enhance patient experience.

The New York Health Information Network will provide interoperability, applications and services using the cloud-based SyntraNet connected healthcare platform from Thrasys. SyntraNet provides an open foundation for highly scalable collaborative healthcare networks. The New York Health Information Network will implement a health information exchange to meet interoperability requirements for ‘Meaningful Use’ and deliver a range of applications and services: electronic health records, practice management services, e-prescribing, group purchasing, insurance and eligibility verification, remote charge capture, physician quality reporting, patient portals, and services to enable accountable care organizations and patient medical homes.

Ramesh Balakrishnan, CEO of Thrasys, stated, “The New York Health Information Network is a first step in our vision to use disruptive technologies to enable a new model for collaborative care. Our goal with Connected Healthcare is to evolve an open healthcare platform that provides core interoperability, applications and services and also enables third-parties and partners to offer a range of add-on solutions. This kind of open, connected and collaborative technology platform is the necessary foundation to support initiatives currently underway to coordinate care, improve outcomes and manage costs. With more than $500m in HITECH funding for HIE initiatives, we will continue to partner with communities of physicians, hospitals, service center, and health plans to implement showcases for the future of healthcare.”

Ray Vuono, CEO of MedLink, continued, “The Health information Network provides a financial benefits for the NYHIN partners including Providers, establishing a revenue model through member based services for as little as $500 per member annually. The products and services are provided by healthcare vendors and service providers that leverage the platform to provide their services to HIN population of physicians, medical facilities, and patients; providing a Web 2.0 healthcare super highway income model similar to that of the iPhone Apps marketplace or Salesforce.com.”

Scott Einiger, Senior Partner at Abrams Fensterman, a leading New York healthcare law firm, commented, “The New York Health Information Network will enable physicians to level the playing field and have access to core health care products and services critical to success in this rapidly evolving healthcare landscape. As physicians join this Network, the quality of the products and services will expand exponentially making available the best of breed applications and services due to substantial Vendor commitment to grow within the Network. I expect this network to grow beyond NY State and become a nationally connected Network enuring to the benefit of patients and physicians alike and greatly enhancing our federal government’s health law reform initiative.”

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

OAKBROOK TERRACE, IL–(Marketwire – October 21, 2010) –  An estimated 80 percent of serious medical errors involve miscommunication between caregivers when responsibility for patients is transferred or handed-off. Recognizing this as a critical patient safety issue, a group of 10 leading U.S. hospitals and health care systems teamed up with the Joint Commission Center for Transforming Healthcare to use new methods to find the causes of and put a stop to these dangerous and potentially deadly breakdowns in patient care.

Health care organizations have long struggled with the process of passing necessary and critical information about a patient from one caregiver to the next, or from one team of caregivers to another. A hand-off process involves “senders,” the caregivers transmitting patient information and releasing the care of the patient to the next clinician, and “receivers,” the caregivers who accept the patient information and care of the patient.

 The Hand-off Communications Project began in August 2009. During the measure phase of the project, the participating hospitals found that, on average, more than 37 percent of the time hand-offs were defective and didn’t allow the receiver to safely care for the patient. Additionally, 21 percent of the time senders were dissatisfied with the quality of the hand-off. Using solutions targeted to the specific causes of an inadequate hand-off, participating organizations that fully implemented the solutions achieved an average 52 percent reduction in defective hand-offs.

The 10 hospitals and health systems that volunteered to address hand-off communications as a critical patient safety problem are:

• Exempla Lutheran Medical Center, Wheat Ridge, Colorado
• Fairview Health Services, Minneapolis, Minnesota
• Intermountain Healthcare LDS Hospital, Salt Lake City, Utah
• The Johns Hopkins Hospital, Baltimore, Maryland
• Kaiser Permanente Sunnyside Medical Center, Clackamas, Oregon
• Mayo Clinic Saint Marys Hospital, Rochester, Minnesota
• New York-Presbyterian Hospital, New York
• North Shore-LIJ Health System Steven and Alexandra Cohen Children’s Medical Center, New Hyde Park, New York
• Partners HealthCare, Massachusetts General Hospital, Boston
• Stanford Hospital & Clinics, Palo Alto, California

Although The Joint Commission requires accredited organizations to use a standardized approach to hand-off communications, breakdowns in communication have been a leading contributing factor in sentinel events, which are unexpected occurrences involving death or serious physical or psychological injury, or the risk thereof. In addition to patient harm, defective hand-offs can lead to delays in treatment, inappropriate treatment, and increased length of stay in the hospital.

Recognizing that there is no quick fix, the Center and the participating hospitals set out to solve the problems through the application of Robust Process Improvement™ tools. RPI is a fact-based, systematic, and data-driven problem-solving methodology that allows project teams to discover specific risk points and contributing factors, and then develop and implement solutions targeted to those factors to increase overall patient safety and health care quality. Barriers to effective hand-offs experienced by receivers include incomplete information, lack of opportunity to discuss the hand-off, and no hand-off occurred. Senders identified too many delays, receiver not returning a call, or receiver being too busy to take a report as reasons for hand-off failures.

 “These 10 organizations are leading the way in finding specific solutions to the complex problem of hand-off communication failures,” says Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission. “A comprehensive approach that focuses on systems is the only way to ensure that the many caregivers upon whom patients rely are successfully communicating vital information during these transitions in care.”

The targeted hand-off solutions from the Center, which are described using the acronym SHARE, address the specific causes of unsuccessful hand-offs. SHARE refers to:

• Standardize critical content, which includes providing details of the patient’s history to the receiver, emphasizing key information about the patient when speaking with the receiver, and synthesizing patient information from separate sources before passing it on to the receiver.
• Hardwire within your system, which includes developing standardized forms, tools and methods, such as checklists, identifying new and existing technologies to assist in making the hand-off successful, and stating expectations about how to conduct a successful hand-off.
• Allow opportunity to ask questions, which includes using critical thinking skills when discussing a patient’s case as well as sharing and receiving information as an interdisciplinary team (e.g., a pit crew). Receivers should expect to receive all key information about the patient from the sender, receivers should scrutinize and question the data, and the receivers and senders should exchange contact information in the event there are any additional questions.
• Reinforce quality and measurement, which includes demonstrating leadership commitment to successful hand-offs such as holding staff accountable, monitoring compliance with use of standardized forms, and using data to determine a systematic approach for improvement.
• Educate and coach, which includes organizations teaching staff what constitutes a successful hand-off, standardizing training on how to conduct a hand-off, providing real-time performance feedback to staff, and making successful hand-offs an organizational priority.

In addition to hand-off communications, the Center is aiming to reduce surgical site infections (SSI) following colorectal surgery through a new project launched in August 2010 in collaboration with the American College of Surgeons. Participating organizations include the Mayo Clinic, OSF Saint Francis Medical Center, Cedars-Sinai Medical Center, North Shore-LIJ Health System, Cleveland Clinic, Stanford Hospital & Clinics and Northwestern Memorial Hospital. The solutions for this project are expected to be published in the fall of 2011.

All Joint Commission-accredited health care organizations have access to the solutions through the Targeted Solutions Tool™ (TST), which provides a step-by-step process to measure performance, identify barriers to excellent performance, and implement the Center’s proven solutions that are customized to address an organization’s specific barriers. The first set of targeted solutions, created by eight of the country’s leading hospitals and health care systems working in collaboration with the Center, focuses on improving hand hygiene. Accredited organizations can access the TST and hand hygiene solutions on their secure Joint Commission Connect extranet. The targeted solutions for hand-off communications are currently being pilot tested to prove their effectiveness in demographically diverse hospitals and will be added to the TST in the second half of 2011. A project to reduce the risk of wrong site surgery is also in process. Future projects are expected to focus on preventable hospitalizations, medication errors, and other aspects of infection control.

Statements from the Center’s participating hospitals
“The communication that is involved in patient transfers is a critical concern that can have a severe impact on care. Therefore, we are pleased to participate in The Joint Commission’s Hand-off Communications Project to find ways of improving this process. I am proud of our employees and their efforts. It is rewarding to know that their work combined with similar activities at the other project participant sites will help improve patient-centered health care across the country.”
Michael J. Dowling, president and CEO, North Shore-LIJ Health System

 “This work demonstrates a new and exciting way to deliver safer care. By collaborating with leading institutions around the country, we’re identifying proven strategies that improve communications during critical points of transfer for our patients.”
Mark Eustis, president and CEO, Fairview Health Services

“Patients’ safety is greatly enhanced when we have smooth and effective communication hand-offs as patients move across care settings. So, patients everywhere will benefit from what we and the other leading health care programs have learned in this collaborative effort with The Joint Commission. This initiative greatly increases the chances for good, safe continuity of care for everyone.”
Susan Mullaney, administrator, Kaiser Permanente Sunnyside Medical Center

“Partners HealthCare frequently collaborates with other institutions across the nation on patient quality and safety initiatives — but has never worked with such a comprehensive group at the same time. This collaboration has produced results beyond the capability of any single participant and validates The Joint Commission’s proposition that critical issues in health care can be addressed in a rigorous and thoughtful way. I know that our patients, and patients across the country, will reap benefits from this work.”
Terrence O’Malley, M.D., medical director, Non-Acute Care Services, Partners HealthCare, Massachusetts General Hospital

“We know that breakdowns in communication that can occur when patients are handed-off from one caregiver to another are a leading cause of patient harm and medical errors. Few areas within the spectrum of patient care give us such an enormous opportunity to improve patient outcomes and reduce mistakes as improving these communications. The Joint Commission’s initiative in this area is a welcome start.”
Ronald R. Peterson, president, The Johns Hopkins Hospital and Health System, and executive vice president, Johns Hopkins Medicine

“We believe that this has been an outstanding project and we are thrilled to have been a participant. Hand-off communication is critical to the patient care process. Being able to identify where there are breakdowns in the hand-off process and focus on where we can improve, as well as develop targeted solutions, will improve the quality of care our patients receive.”
Kevin Tabb, M.D., CMO, Stanford Hospital & Clinics

 “Exempla Lutheran Medical Center is proud to participate in the Joint Commission Center for Transforming Healthcare’s critical initiative to improve the quality of hand-off communications. We know how important it is to communicate accurately and effectively when we transfer patients from one caregiver to another. But what is it that interferes with those communications? Working with the Center and the other participating hospitals, and with the use of Lean Six Sigma, we identified some of the critical barriers to effective communication to establish processes that can be replicated to consistently make patient transfers safer. We are committed to working with the Center and the other participating hospitals to help solve these complex patient safety issues and share best practices.”
Grant Wicklund, president and CEO, Exempla Lutheran Medical Center

The Center is grateful for the generous leadership and support of the American Hospital Association, BD, Ecolab, GE Healthcare, GlaxoSmithKline (GSK), Johnson & Johnson and Medline Industries, as well as the support of GOJO Industries, Inc. and The Federation of American Hospitals.

For more information about the Joint Commission Center for Transforming Healthcare, visit www.centerfortransforminghealthcare.org.

Established in 2009, the Joint Commission Center for Transforming Healthcare aims to transform American health care into a high-reliability industry that ensures patients receive the safest, highest quality care they expect and deserve. The Center’s participants – the nation’s leading hospitals and health systems – use a proven, systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions for health care’s most critical safety and quality problems. The Center is a not-for-profit affiliate of The Joint Commission, which shares the Center’s proven effective solutions with its more than 18,000 accredited health care organizations. Learn more about the Center at www.centerfortransforminghealthcare.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_01021_miscommunication/index.html

Click here to see all recent news from this company

ARLINGTON, VA–(Marketwire – October 21, 2010) –  Vangent, Inc., a leading global provider of information management and strategic business process solutions, announced today it was awarded a $15.6 million contract by the Office of the National Coordinator (ONC) for Health Information Technology to promote the adoption of health information technology, improve methods of health information exchange (HIE) and provide subject matter expertise as program manager for the Federal Health Architecture (FHA) and CONNECT initiative.

Under the contract, Vangent will provide ONC with program management and health IT management consulting capabilities and run the FHA and CONNECT Program Management Office (PMO). This contract award also calls for Vangent’s health IT subject matter experts to work directly with federal healthcare agencies such as the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) to increase adoption of the CONNECT solution.

“Vangent is pleased to continue advancing the adoption of CONNECT and other FHA initiatives and to work with the federal government to ensure that all citizens have electronic health records by 2014,” said Mac Curtis, President and CEO, Vangent. “By providing technical solutions like Health Information Exchange Open Source (HIEOS™) that serve as part of the CONNECT solution stack, in addition to consulting and program management services to the FHA PMO, Vangent helps ONC work towards its goal of improved quality of care and increased program efficiency.”

Vangent serves as program manager for the National Health Information Network CONNECT Gateway solution, which was named one of the most innovative technologies of the year by The Wall Street Journal.  The CONNECT software, of which Vangent’s HIEOS™ solution is a part, is an open source software solution that uses standards and governance to ensure that HIEs are compatible with one another, both locally and at the national level. Vangent’s HIEOS™ solution was selected by the Office of the National Coordinator (ONC) as the default XDS.b registry (record locator services) and repository (record storage services) implementation in the CONNECT Gateway in October 2009.

Under the new contact, Vangent will also support FHA integration with the National Health Information Network Standards and Interoperability (S&I) Framework and federal involvement with the National Health Information Network DIRECT project. The Vangent Team will also manage FHA and CONNECT operational performance and financial tasks. The Vangent team of partners (Iris Partners, SAIC, and Spire Communications) has already built a solid foundation of success from its previous work with the FHA and CONNECT, serving as manager of the FHA Program Management Office since its inception in 2004 and and program manager for the CONNECT initiative since its inception in 2006.

The maximum duration of the contract with FHA is five years, and if all options are exercised, the value of the contract is $15.6 million.

“Vangent’s work with the Office of the National Coordinator for Health Information Technology has enriched our team’s experience in the health IT industry,” said Kerry Weems, Senior Vice President and General Manager of Vangent’s Health Solutions business. “Technology is quickly changing the way healthcare organizations exchange critical data, and Vangent is honored to be a part of these exciting initiatives.”

About Vangent, Inc.
Vangent, Inc. is a global provider of consulting, systems integration, human capital management, and business process services to the U.S. federal and international governments, higher education institutions, and corporations. Vangent’s 8,000 employees support clients including the Centers for Medicare & Medicaid Services, the U.S. Departments of Defense, Education, Health and Human Services, Labor and Veterans Affairs; and the U.S. Office of Personnel Management, as well as Fortune 500 companies. Headquartered in Arlington, Virginia, the company has offices throughout the U.S. and in the U.K. and Canada. For more information, visit www.vangent.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are those that do not relate solely to historical fact. They include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “will,” “would,” “could” and similar expressions or phrases identify forward-looking statements. All forward-looking statements involve risks and uncertainties. The occurrence of the events described, and the achievement of the expected results, depend on many events, some or all of which are not predictable or within our control. In light of these risks and uncertainties, expected results or other anticipated events or circumstances discussed in this press release might not occur. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NORTHFIELD, IL–(Marketwire – October 21, 2010) –  Randall E. Williams, MD, CEO and founder of Pharos Innovations, has been elected to chair the Government Affairs Committee of the Care Continuum Alliance, an organization focused on strategies to improve healthcare quality and outcomes and reduce preventable costs. As chair of the Government Affairs Committee, Dr. Williams will provide leadership and oversight for the committee’s work including the development of position statements on emerging public policy issues, as well as monitoring healthcare policy to provide Care Continuum Alliance members with valuable information and research on key legislative and regulatory issues. Dr. Williams is also a member of the Alliance’s Executive Committee, which is comprised of healthcare leaders from health plans, academia, wellness organizations and other health management stakeholders.

“I am very honored to have been selected to chair The Care Continuum Alliance’s Government Affairs Committee. I hope to draw from my past work with key Congressional committees, HHS and CMS as we work to accomplish the ‘triple aim’ of improving healthcare quality, reducing healthcare costs and improving the health of populations and sustainability of our healthcare system,” said Williams. “The Care Continuum Alliance is a thought-leadership organization with a wealth of collective experience moving in the right direction toward these aims, and I am excited to be part of this movement.”

Under Dr. Williams’ leadership, Pharos Innovations developed Tel-Assurance^®, a device-free, cost effective, remote patient monitoring platform that does not require special equipment. Tel-Assurance has helped Medicare, Medicaid and commercial patients and their physicians achieve break-through levels of clinical and financial performance improvement, including several successful CMS demonstrations.

“Dr. Williams brings exceptional credentials and experience to our Government Affairs Committee,” Care Continuum Alliance President and CEO Tracey Moorhead said. “His leadership will be invaluable as healthcare reform moves through the regulatory process.”

About the Care Continuum Alliance
The Care Continuum Alliance convenes all stakeholders providing services along the continuum of care for population health improvement, including health and wellness promotion, chronic care management and care coordination. Through advocacy, research and promotion of best practices, the Care Continuum Alliance advances population-based strategies to improve care quality and outcomes and reduce preventable costs for individuals with and at risk of chronic conditions. The Care Continuum Alliance represents more than 200 corporate and individual stakeholders, including wellness and care management organizations, pharmaceutical manufacturers and benefits managers, health information technology and biotechnology innovators, employers, hospitals, physicians, nurses and other health care professionals, and researchers and academics. Learn more at http://www.carecontinuum.org.

About Pharos Innovations
Pharos Innovations is actively involved in transforming the U.S. healthcare delivery system. Pharos offers IVR and Web-based behavior change services and tools that enable payers and providers to cost-effectively and efficiently manage their chronic care population.

Pharos’ main offering, Tel-Assurance, engages, motivates and drives improved self-care. Through Tel-Assurance, participants self-report their health status daily through the phone or Web. This unique approach actively engages individuals with chronic conditions in their healthcare and provides care managers/nurses with real-time information to intervene before symptoms escalate. Tel-Assurance has been proven an effective way to reduce avoidable, all-cause hospital admissions and readmissions and reduce overall healthcare costs among diverse populations.

The Pharos’ solution is strongly validated to show measured clinical improvement and financial impact, is the recipient of the prestigious American Heart Association National Outcomes award and was selected for the first ever National Institutes of Health (NIH) sponsored evaluation of remote monitoring interventions. For more information visit http://www.pharosinnovations.com or join in on the discussion at our blog, http://www.thecollaborativeforum.com.

id=”nav_links”>

BOSTON, MA–(Marketwire – October 21, 2010) –  Virgin HealthMiles, a leading provider of employee health and productivity programs that reward individuals for getting healthy, today announced it will host a free webinar sharing how to keep employees engaged in workplace wellness programs and proven strategies employers can implement to drive higher participation in their employee health promotion efforts.

The webinar, “Promoting Participation: What Keeps Employees Engaged?” will be held Wednesday, October 27, 2010, from 2:00 p.m. – 3:00 p.m. ET.

Participation in traditional employee health programs averages less than 15 percent, while Virgin HealthMiles’ participation averages 40 percent. During this webinar, Virgin HealthMiles’ Senior Vice President of Marketing and Member Engagement, Tom Abshire, and Senior Director of Client Services, Ed Dougherty, will share survey results from employees and best practices from clients regarding effective strategies they’ve implemented to successfully impact employee participation in their corporate health programs, including:

• Financial incentives
• Goal setting and tracking
• Challenges and competitions
• Social engagement

Participants will discover how the combination of incentives, leading technology, and a positive employee experience provide the motivation and tools employees need to stick with workplace health programs and their new, healthy behaviors for the long term.

To register for the live webinar, please visit:
http://event.on24.com/r.htm?e=254014&s=1&k=ADB371478B811161097B6D540121D36B&partnerref=VHMPress

A free recording of the webinar will be available on the Virgin HealthMiles website at: www.virginhealthmiles.com. 

About Virgin HealthMiles
Virgin HealthMiles provides employee health programs that pay people to get active. The company’s Pay-for-Prevention™ approach, based on physical activity and healthy lifestyle change, attracts an average of 40 percent of employees who participate, which helps organizations reduce medical costs and improve employee productivity and satisfaction. The program is offered by employers, government entities, and insurers. Over 120 industry leaders representing more than 500,000 employees across the U.S., including American Diabetes Association, Intuit, OhioHealth, Ochsner Health System, MWV, Protective Life, SunGard, SunTrust, and Timberland have selected Virgin HealthMiles’ award-winning program for their employees. The company is a member of Sir Richard Branson’s Virgin Group. For more information, visit www.virginhealthmiles.com

Click here to see all recent news from this company

EDMONTON, ALBERTA–(Marketwire – 21 oct. 2010) – Medtronic, Inc. (NYSE:MDT) a annoncé aujourd’hui le lancement au Canada d’une technologie inédite conçue pour assurer une protection accrue contre les risques associés à l’hypoglycémie. Ce nouveau dispositif, désormais offert au Canada ainsi que dans une cinquantaine de pays à l’extérieur des États-Unis, peut automatiquement interrompre l’administration de l’insuline lorsqu’il capte une chute ou des taux de glycémie inférieurs à un seuil présélectionné. La nouvelle fonction vise à réduire la gravité des crises d’hypoglycémie lorsque les patients oublient ou sont incapables d’y remédier. L’hypoglycémie, un composant dangereux et souvent fréquent du diabète, peut être l’un des aspects les plus effrayants du diabète de type 1. Non traitée, l’hypoglycémie peut causer la perte de conscience, une crise d’épilepsie, le coma ou même le décès.¹

Selon la recherche, une personne atteinte de diabète subit, en moyenne, plus d’une crise d’hypoglycémie aux deux semaines. En outre, environ un diabétique sur 14 traités par insuline vivra, chaque année, au moins une crise grave d’hypoglycémie nécessitant une intervention urgente de la part d’un professionnel de la santé.² Un tiers des diabétiques souffrent d’hypoglycémie pendant le sommeil et peuvent donc ne pas être en mesure de ressentir une crise grave ou de réagir pour la prévenir.³ On estime à 33 pour cent les cas de décès liés au diabète découlant de complications aiguës, comme l’hypoglycémie.⁴ Bien que la plupart des patients reconnaissent les «signes précoces» d’une hypoglycémie (dont la sensation de faiblesse, la sudation, le picotement des lèvres, la confusion et l’irritabilité), de nombreux autres peuvent ne rien ressentir du tout.

«La Paradigm Veo, grâce à son mécanisme automatique de rétroaction, représente un jalon important de notre engagement à améliorer le contrôle glycémique chez les diabétiques», a déclaré M^me Katie Szyman, présidente du groupe Diabète et vice-présidente principale de Medtronic. «Bien qu’il ne s’agisse pas d’une cure pour le diabète, nous croyons que cette fonction automatique rehausse la protection et la confiance et peut diminuer le risque de blessure associé aux crises d’hypoglycémie. Il importe tout autant de souligner la tranquillité d’esprit dont profiteront les patients et les membres de leur famille.»

Le système Paradigm Veo se compose d’une pompe à insuline et de la mesure du glucose en continu (MGC) (assurée par un capteur et un transmetteur distincts). Le patient se sert des lectures faites par le moniteur pour comprendre les tendances actuelles de sa glycémie. Après un prélèvement capillaire de confirmation, le patient programme la pompe à insuline pour qu’elle administre une quantité appropriée d’insuline. L’insuline combat l’hyperglycémie, l’une des principales causes des maladies cardiaques et d’autres complications à long terme du diabète de type 1.¹ Toutefois, si les données transmises par le capteur indiquent une chute de la glycémie sous un seuil déterminé à l’avance, l’instrument alerte le patient. Si ce dernier ignore ces signaux d’alarme, la pompe à insuline interrompt automatiquement l’administration d’insuline jusqu’à deux heures d’affilée. Cette fonction contribue ainsi à le protéger contre des périodes d’hypoglycémie potentiellement dangereuses. 

«Cette toute dernière technologie représente un jalon significatif. Elle aidera les diabétiques à optimiser le contrôle de leur glycémie de façon plus sécuritaire. Pour réduire le risque à long terme de complications liées au diabète, dont la cécité, l’insuffisance rénale et les crises cardiaques, les patients devraient maintenir leur glycémie à des taux les plus proches possibles de la normale. Malheureusement, un contrôle rigoureux de la glycémie accentue le risque d’hypoglycémie grave, ce qui peut rendre un patient inconscient et, en cas de crises répétées, peut avoir des conséquences très sérieuses», mentionne le docteur Bernard Zinman, directeur du Leadership Sinai Centre for Diabetes de l’Hôpital Mount Sinai de Toronto. «Pour la première fois, une pompe à insuline peut non seulement prévenir le patient de cette situation dangereuse, mais aussi y réagir pour ainsi corriger cette situation indésirable. Le système Paradigm Veo avertit les patients que leur glycémie est trop basse et arrête l’administration de plus ample quantité d’insuline s’ils ne réagissent pas à l’avertissement. Cette fonction de sécurité peut permettre aux patients de mieux contrôler leur hypoglycémie grave.»

Au sujet du groupe Diabète de Medtronic

Le groupe Diabète de Medtronic (www.medtronicdiabetes.com) est un chef de file mondial en solutions de pointe pour la gestion du diabète, notamment des systèmes intégrés de gestion du diabète, le traitement par pompe à insuline, des système de mesure du glucose en continu et un logiciel de gestion thérapeutique, ainsi que des services et un soutien hors pair à l’intention du grand public et des professionnels, 24 heures sur 24, 7 jours sur 7.

Au sujet de Medtronic

Medtronic, Inc. (www.medtronic.com), dont le siège social se trouve à Minneapolis, est le chef de file mondial de la technologie médicale visant à soulager la douleur, rétablir la santé et prolonger la vie de millions de gens, à l’échelle planétaire. De plus amples renseignements sont offerts sur : www.medtronic.com.

Toutes les déclarations sur les résultats financiers anticipés sont assujetties à des risques et à des incertitudes, tels qu’ils sont énoncés dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission (Commission des valeurs mobilières des États-Unis). Les résultats réels pourraient différer sensiblement des résultats anticipés.

Au sujet de Medtronic du Canada Ltée 

Medtronic du Canada Ltée, vend, entretient et distribue les produits de Medtronic au Canada : des instruments médicaux pour le traitement des maladies cardiaques et vasculaires et du diabète, pour la chirurgie de la colonne vertébrale, la neurochirurgie ainsi que pour la chirurgie oto-rhino-laryngologique. Medtronic du Canada, dont le siège social se trouve à Brampton, en Ontario, emploie plus de 420 Canadiens répartis dans son centre d’opérations de Mississauga et ses bureaux régionaux de Vancouver et Montréal. Elle exploite également une usine de mise au point et de fabrication de cathéters d’ablation pour la fibrillation auriculaire (FA) – Medtronic CryoCath – dans la région métropolitaine de Montréal.

Références

1. Diabetes UK: http://www.diabetes.org.uk/Guide-to-diabetes/Complications/Hypoglycaemia/ (Consulté le 23 avril 2009)

2. Leese GP, Wang J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 26:1176-1180, 2003.

3. Pramming S, Thorsteinsson B et al. Nocturnal hypoglycemia in patients receiving conventional treatment with insulin. British Medical Journal 291(1985):376-379

4. Orchard TJ. International evaluation of cause-specific mortality and IDDM. Diabetes Care 14:55-60, 1991

EDMONTON, ALBERTA–(Marketwire – Oct. 21, 2010) – Medtronic, Inc. (NYSE:MDT) announced today the Canadian launch of a novel technology designed to provide additional protection against the risks associated with hypoglycemia. This new device, currently available in more than 50 countries outside of the United States and now in Canada, can automatically suspend insulin delivery when the device senses that glucose levels have fallen to or below a pre-selected threshold. This feature is intended to reduce the severity of low blood sugar (hypoglycemia) in situations where patients ignore or are unable to treat hypoglycemia. Hypoglycemia, a dangerous and often frequent occurrence with diabetes, can be one of the most frightening aspects of living with type 1 diabetes. If left untreated, hypoglycemia can cause loss of consciousness, seizure, coma, or even death.¹

Research indicates that, on average, a person with diabetes will experience more than one low blood sugar event every two weeks. Additionally, each year, nearly one in 14 people with insulin-treated diabetes will experience one or more episodes of severe hypoglycemia, requiring urgent treatment by a healthcare professional.² A third of diabetes patients suffer from hypoglycemia while asleep, which may impair their ability to recognize or act to prevent a serious episode.³ An estimated 33 percent of diabetes-related deaths are a result of acute complications such as hypoglycemia.⁴ While most patients experience “warning signs” before a hypoglycemic event (such as feeling shaky, sweating, tingling in the lips, confusion and irritability), many others may not experience any warning signs at all.

“The Paradigm Veo, with its automatic feedback mechanism, is a major step forward in our commitment to improving glucose control in diabetics,” says Katie Szyman, president of the Diabetes business and senior vice president at Medtronic. “While not a cure for diabetes, we believe this automatic feature offers added protection, greater confidence and may lower the risk of injury associated with hypoglycemic events. Equally important, it will give patients and family members more peace of mind.”

The Paradigm Veo System includes an insulin pump with a continuous glucose monitoring (CGM) system (provided by means of a separate sensor and transmitter). The patient uses readings from the monitor to understand their current glucose level changes. Based on confirmatory fingerstick blood glucose measurements, the patient then programs the insulin pump to deliver an appropriate amount of insulin. Insulin combats high blood sugar, a key cause of heart disease and other long-term complications in type 1 diabetes.¹ However, if data transmitted from the sensor show the patient’s glucose levels have dropped below a defined threshold, the device alarms to alert the patient. If these alarms are ignored, the insulin pump automatically suspends insulin delivery for up to two hours. This helps to protect against potentially dangerous hypoglycemic events. 

“This latest technology is a significant advance that will help people with diabetes to more safely optimize glucose control. In order to reduce the long-term risk of diabetes-related complications, which can cause blindness, kidney failure and heart attacks, patients should manage their glucose levels to as near normal as possible. Unfortunately, aggressive glucose control can increase the risk of severe hypoglycemia, which can render a patient unconscious—and if recurrent—can have very serious consequences,” says Dr. Bernard Zinman, Director of the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital in Toronto. “For the first time, an insulin pump can now not only warn the patient of this dangerous situation but can also respond and thus help correct this undesirable situation. The Paradigm Veo alerts patients if their glucose levels drop too low, and stops the delivery of more insulin if they don’t respond to the alert. Having this safety feature may allow patients greater control over severe hypoglycemia.”

About the Diabetes Business at Medtronic

The Diabetes business at Medtronic (www.medtronicdiabetes.ca) is the world leader in advanced diabetes solutions, including integrated diabetes management systems, insulin pump technology, continuous glucose monitoring systems and management software, as well as world-class, 24/7 expert consumer and professional service and support.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world. More information is available at: www.medtronic.com.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

About Medtronic of Canada Ltd.

Medtronic of Canada sells, services and distributes Medtronic products in Canada: medical devices used in cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs over 420 Canadians, it is headquartered in Brampton, Ontario, has an Operations Centre in Mississauga and regional offices in Vancouver and Montreal and an atrial fibrillation (AF) ablation catheter manufacturing facility – Medtronic CryoCath – in the Montreal metropolitan area.

References

1. Diabetes UK: http://www.diabetes.org.uk/Guide-to-diabetes/Complications/Hypoglycaemia/ (Accessed 23^rd April 2009)

2. Leese GP, Wang J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 26:1176-1180, 2003.

3. Pramming S, Thorsteinsson B et al. Nocturnal hypoglycemia in patients receiving conventional treatment with insulin. British Medical Journal 291(1985):376-379

4. Orchard TJ. International evaluation of cause-specific mortality and IDDM. Diabetes Care 14:55-60, 1991

AURORA, ON–(Marketwire – October 21, 2010) –  Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced positive efficacy and safety findings from its recently completed Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. These findings build upon the positive pharmacokinetic findings from this study announced in the Company’s press release of June 23, 2010.

Using colposcopic directed biopsy to determine the treatment’s effectiveness, 71.4% of the women in the study no longer had potentially pre-cancerous, low-grade lesions known as cervical intraepithelial neoplasia grade 1 or 2 (CIN 1 or CIN 2) following treatment. Colposcopic directed biopsy is generally considered the leading method for diagnosing potential cervical precancer today. In addition, Topical Interferon Alpha-2b demonstrated an excellent safety profile, with no significant local intolerance findings and no serious adverse events.

There are approximately 1.3 million women diagnosed with CIN 1 or CIN 2 lesions each year in the U.S. alone. Currently, there are no pharmaceutical (non-surgical) treatments for these women. Available invasive/surgical techniques to treat CIN 1 or CIN 2 lesions are sometimes associated with serious unwanted side effects for patients, including cervical complications with pregnancy and conception. Accordingly, available invasive/surgical techniques are generally utilized only in the case of many months of long-term persistence and/or progression of CIN 1 or CIN 2 lesions, leaving patients uncertain and anxious about their prognosis in the interim.

“We are pleased with these findings because they provide further evidence of the potential effectiveness of Topical Interferon Alpha-2b for treating women with potentially precancerous, low-grade cervical lesions,” said John Docherty, president of Helix BioPharma Corp. “These findings suggest that Topical Interferon Alpha-2b could offer women a safe and immediate therapeutic alternative to today’s protracted observational and potentially problematic surgical approach to managing this disease. We are now awaiting approval by the U.S. Food and Drug Administration of our application to conduct an expanded U.S. Phase II/III randomized, double-blind, controlled, pivotal efficacy trial in patients with low-grade cervical lesions.”

The study also examined Papanicolaou (“Pap”) smear response rate as a secondary efficacy parameter in the patients. The finding was less pronounced with 35.7% of the women demonstrating resolution of their abnormal Pap smears. However, this study was specifically designed with a relatively short post-treatment follow-up period as it was principally intended to provide pharmacokinetic results. The Company was, therefore, not surprised by this finding. By comparison, the Company has previously reported a more pronounced Pap response rate in patients treated with Topical Interferon Alpha-2b when it employed a longer post-treatment follow-up period.

About the Clinical Study

The clinical study employed an open-label, single-arm design and enrolled a total of 14 female patients with low-grade cervical lesions. Eligible women were between 18 and 45 years of age, presented with mild to moderate CIN (CIN1 or CIN2 respectively) confirmed by biopsy/histology, had a cytological diagnosis of Pap IIID not older than 12 months and were human papillomavirus (HPV)-positive confirmed by the Hybrid Capture^® 2 HPV-DNA test. The primary objective of the study was to determine the multiple-dose pharmacokinetic profile of Topical Interferon Alpha-2b following intravaginal application every other day of a total of 14 doses of the cream. Helix previously announced on June 23, 2010 that all 14 patients were found to have circulating interferon alpha-2b levels below the bioassay lower limit of detection (6.25 pg/mL) at all sampling time points. Following the pharmacokinetic portion of the trial, assessment of the secondary efficacy and safety parameters continued until 35 doses of the cream were applied. As such, the clinical study was designed to also mimic the dosing regimen intended to be applied in Helix’s planned U.S. Phase II/III and European Phase III pivotal efficacy trials for this indication. The clinical study was conducted under the direction of Prof. Dr. med. Achim Schneider, M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynecology at the Charité University Hospital in Berlin, Germany.

About CIN 1 and CIN 2

CIN 1 and CIN 2 are potentially precancerous, low-grade cervical lesions detectable upon colposcopic directed biopsy. There are approximately 1.3 million women diagnosed with CIN 1 or CIN 2 lesions each year in the U.S. alone, according to data from 2006 Consensus Guidelines in the American Journal of Obstetrics and Gynecology 2007; 340-345 and Kaiser Permanente Northwest Health Plan in the American Journal of Obstetrics and Gynecology (2004) 191, 105-13. Currently there are no pharmaceutical (non-surgical) treatments for women with CIN 1 or CIN 2 lesions. Available invasive/surgical techniques to treat CIN 1 or CIN 2 lesions are sometimes associated with serious unwanted side effects for patients including cervical complications with pregnancy and conception. For patients with CIN 1 or CIN 2 lesions, clinical management usually consists of protracted watchful waiting with frequent Pap smears, HPV testing, colposcopy and/or colposcopic directed biopsies, with invasive/surgical techniques generally utilized only in the case of long-term persistence and/or progression after a period of many months. A diagnosis of CIN 1 or CIN 2 leads to frequent physician visits, procedures, and psychosocial stress for the patient. The goal of developing Topical Interferon Alpha-2b is to provide a safe and effective treatment for CIN 1 or CIN 2 at the time of diagnosis, as a proactive alternative to today’s often protracted observational management approach.

About Topical Interferon Alpha-2b

Interferon alpha-2b is a potent cytokine that possesses antiviral, immunomodulatory and antiproliferative activities with activity against HPV. Topical Interferon Alpha-2b is a semi-solid formulation of recombinant interferon alpha-2b based on Helix’s Biphasix™ platform drug formulation technology. This technology involves the formation of biphasic lipid vesicles for use as a vehicle for administration of a biologically active material encapsulated within the lipid bilayers. Topical Interferon Alpha-2b has been developed as a cosmetically appealing cream dosage form that can be easily and conveniently self-applied intravaginally for the treatment of low-grade cervical lesions using a common vaginal applicator.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and FSE under the symbol “HBP”. For more information, please visit www.helixbiopharma.com.

Forward-Looking Statements and Risks and Uncertainties

This News Release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”), within the meaning of applicable securities laws, regarding the Company’s plans for the development of Topical Interferon Alpha-2b in patients with low grade cervical lesions; the effectiveness of Topical Interferon Alpha-2b and its role as a therapeutic alternative; its planned designs for such proposed trial as well as its proposed European Phase III clinical trial; the development of Helix’s L-DOS47 and Topical Interferon Alpha-2b new drug candidates; and other information in future periods. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions which have been applied in making such forward-looking statements, include, but are not limited to, assumptions regarding the safety and efficacy of Helix’s drug candidates; the timely receipt of necessary regulatory approvals and appropriate financing and strategic partner support; the timely and successful completion of the proposed U.S. and European clinical trials; and that the Company’s drug candidates will ultimately be successfully developed and commercialized. Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, that the Company’s assumptions may prove to be incorrect; the Company’s continuing need for additional capital and for substantial funding beyond its current resources, as well as strategic partner support, to conduct the proposed U.S. and European trials, which are not assured; regulatory approvals to conduct the planned U.S. and European trials may be delayed or denied; the fact that results in earlier clinical studies may not be repeated in later clinical trials, and one or both of the planned clinical trials could fail; the failure of the European trial could have a material adverse impact on the U.S. trial and FDA approval; the need for further regulatory approvals, which are not assured; the Company’s dependence on performance by its third party providers of intellectual property, services and supplies, including without limitation, clinical trial services and supplies of drug product; the risk that Helix’s supplier of interferon alpha-2b may not continue to provide necessary supplies or exercise its commercialization option; the risk that the design or duration, or both, of the planned clinical trials may be different than currently intended; the potential need for further clinical trials beyond those mentioned in this news release which may not occur as planned or achieve expected results; product liability and insurance risks; risks and uncertainties related to research and development, including clinical trial and manufacturing risks; intellectual property risks, including without limitation, the risk that three patents for Topical Interferon Alpha-2b will expire in 2013 and no additional patent may be issued, which may negatively impact the further development or commercialization of the drug candidate; the effect of competition and the fact that there are a number of other companies developing potentially competitive products; uncertainties related to economic conditions; uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be successfully developed and commercialized; exchange rate risk; and the risk of changes in business strategy or development plans. Investors should consult the Company’s quarterly and annual filings, including its latest Form 20-F, with the Canadian and U.S. securities commissions at www.sedar.com and at www.sec.gov for additional information on these and other risks and uncertainties which may affect the Company. Investors are cautioned against placing undue reliance on forward-looking statements. Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix’s management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, assumptions, opinions or expectations change, except as required by securities law.

PLYMOUTH, MN–(Marketwire – October 20, 2010) – November is American Diabetes Month® and Miracle-Ear is joining in a nationwide call to action to involve individuals and organizations in the movement to Stop Diabetes®. Over the next several months, Miracle-Ear will sponsor the American Diabetes Association‘s educational and fundraising events such as walks, bike tours and Association consumer EXPO events. This national strategic partnership will help emphasize the urgency of reducing the devastating impact — including hearing loss — of diabetes.

Today, nearly 24 million U.S. children and adults — nearly 8% of the population — have diabetes, and another 57 million individuals have prediabetes. If current trends continue, one out of every three American children born today will face a future with diabetes. For some high-risk populations, the risk is one in two. According to the American Diabetes Association, diabetes is a growing epidemic and is taking a devastating physical, emotional and financial toll on our country.

“Simple ‘awareness’ is not enough to change these statistics,” says Rebecca Younk, audiologist for Miracle-Ear. “What we need now is action. Individuals need to make the lifestyle, diet and exercise changes that can help prevent Type 2 diabetes; and we need increased education and outreach about symptoms that can help people seek early treatment before serious complications develop.”

Stop Diabetes is the movement to end the devastating toll that diabetes takes on the lives of millions of individuals and families across our nation. It will inspire and mobilize millions to take up the fight against diabetes.

Miracle-Ear is the first company in the hearing care industry to join the Association as a national strategic partner. Miracle-Ear will support the Stop Diabetes movement in order to shine a spotlight on the hearing-related risks of diabetes, as well as the Association’s education, prevention and treatment initiatives.

“Diabetes doubles your risk of developing a hearing loss,” Younk states. “Early diagnosis and treatment are critical in helping to minimize complications, including hearing loss. Since people with Type 2 diabetes frequently do not display any symptoms, hearing loss may be the first indicator that there may be a problem.”

To focus attention on diabetes and its link to hearing loss, throughout the month of November, all 1,200+ Miracle-Ear locations nationwide will donate $5 toward the Stop Diabetes movement for each Free Hearing Test they conduct — up to a maximum of $50,000. The test measures speech recognition in noise along with loudness discomfort levels; its purpose is to measure the degree of any possible hearing impairment.

“We hope that our involvement with the Stop Diabetes movement will inspire individuals to take meaningful action to Stop Diabetes,” said Younk. The Stop Diabetes movement identifies four primary options that everyone can take: Share your story to inspire others; Act by volunteering and raising funds in your community; Learn the facts about diabetes management, nutrition, lifestyle and prevention; and Give your time and your talents, along with your financial support, to support education, outreach, advocacy and critical research for a cure.

For more information on Miracle-Ear, please visit http://www.miracle-ear.com/. 

About Miracle-Ear
A trusted resource for hearing solutions for over 60 years, Miracle-Ear uses state-of-the-art technology to remove the barriers of hearing loss. The Plymouth, Minn.-based company specializes in customizable hearing solutions that feature discreet, comfortable products designed to meet each individual’s hearing loss needs. Free hearing tests and consultations are available at all of the company’s 1,200 locations across the U.S., many of which are in Sears stores. Franchise opportunities are available for those interested in running their own Miracle-Ear business with the support of a nationwide industry leader. 
For more information, visit www.miracle-ear.com.

SLIDELL, LA–(Marketwire – October 20, 2010) –  Blue Cross and Blue Shield of LOUISIANA has designated SOUTHERN SURGICAL HOSPITAL as a Blue Distinction Center for Bariatric Surgery. To date, more than 230 facilities nationwide have received a Blue Distinction Center for Bariatric Surgery designation.

Obesity is widely recognized as a contributor to serious health risks. According to the Agency for Healthcare Research and Quality (AHRQ), the total number of bariatric surgeries increased 400 percent from 1998 to 2004. Bariatric surgery may help some individuals reduce extreme obesity and its associated health risks, and Blue Distinction provides objective information to help them make informed decisions when choosing a provider.

“SOUTHERN SURGICAL HOSPITAL is proud to receive this distinction from Blue Cross/Blue Shield. We look forward to providing our high level of surgical weight loss services to the Blue Cross/Blue Shield community,” said Michael J Thomas MD, Medical Director Bariatric Program, Southern Surgical Hospital.

SOUTHERN SURGICAL HOSPITAL provides a full range of bariatric surgery care services, including inpatient care, post-operative care, outpatient follow-up and patient education.

Blue Distinction puts a high value on research and evidence-based health and medical information,” says Allan Korn, MD, Blue Cross and Blue Shield Association Chief Medical Officer. “Blue Distinction Centers show our commitment to working with doctors and hospitals in communities across the country to identify leading institutions that meet clinically validated quality standards and deliver better overall outcomes in patient care.”

To be designated as a Blue Distinction Center for Bariatric Surgery, SOUTHERN SURGICAL HOSPITAL met the selection criteria posted at www.BCBS.com, which includes:

• an established bariatric surgery program, actively performing these procedures for the most recent 12-month period and performing a required minimum volume of 125 such surgeries annually
• appropriate experience of its bariatric surgery team
• an acute care inpatient facility, including intensive care and emergency services
• full accreditation by The Joint Commission, Healthcare Facilities Accreditation Program (HFAP) or national equivalent**
• a comprehensive quality management program

Blue Distinction is a designation awarded by Blue Cross and Blue Shield companies to medical facilities that have demonstrated expertise in delivering quality healthcare. The designation is based on rigorous, evidence-based selection criteria established in collaboration with expert physicians’ and medical organizations recommendations.

Today, more than 800 Blue Distinction Center designations have been awarded to facilities nationwide, providing consumers with a framework for making informed decisions on where to go for specialty care in the areas of bariatric surgery, cardiac care, complex and rare cancers, and transplants.

**Note: Designation as Blue Distinction Centers means these facilities’ overall experience and aggregate data met objective criteria established in collaboration with expert clinicians’ and leading professional organizations’ recommendations. Individual outcomes may vary. To find out which services are covered under your policy at any facilities, please call your local Blue Cross and/or Blue Shield Plan.

AUGUSTA, GA–(Marketwire – October 20, 2010) –  The International Association for Continuing Education and Training (IACET) has awarded ESi^® its prestigious Authorized Provider status. IACET Authorized Providers are the only organizations approved to offer IACET continuing education units (CEUs). The recognition period extends for five years and includes all programs offered or created during that time.

“ESi education programs train thousands of emergency management professionals each year in the proper use and administration of our full suite of crisis information management products, including WebEOC^®, WebEOC Mapper, and ESiWebFUSION™,” said Jim Cook, President of ESi University. “Our new partnership with IACET is a demonstration of our commitment to lifelong learning and high standards for all of our programs, and we are very pleased to join such a prestigious organization.”

“We are pleased to welcome ESi as our newest Authorized Provider organization,” said Karen Brown, President of IACET and Senior HR Manager of Nuclear Power at Shaw Group in Massachusetts. “ESi joins nearly 650 organizations around the globe that have had their programs vetted by third-party experts in continuing education to ensure the highest possible standards are met.”

ESi University develops and delivers training courses to ESi customers throughout the world at its state-of-the-art training facility in Atlanta, through its e-learning portal, and via its virtual classroom which allows students and instructors to see and hear each other and share computer screens during courses.

In order to achieve Authorized Provider status, ESi completed a rigorous application process, including a review by an IACET site visitor and successfully demonstrated adherence to the ANSI/IACET 1-2007 Standard addressing the design, development, administration, and evaluation of its programs. ESi has pledged to continue its compliance with the Standard and is now authorized to use the IACET name and Authorized Provider logo on promotional course material. In addition, ESi is now linked to the IACET web site and is recognized as offering the highest quality continuing education and training programs.

About ESi
Augusta, Georgia-based ESi^®, the global leader in crisis information management technology, pioneered the market with WebEOC^®, the world’s first Web-enabled emergency management communications system. Recognized by Inc. Magazine as one of the fastest-growing private companies in America from 2007 through 2010, ESi connects crisis response teams and decision makers at national, state and local agencies, healthcare providers, airlines and corporations worldwide, providing access to real-time information for a common operating picture during a crisis or daily operations. By offering a solutions package from initial design and installation through training, implementation, and maintenance, ESi sets the standard for crisis information management. For more information, please visit www.ESi911.com.

About IACET
The International Association for Continuing Education and Training (IACET) is a non-profit association dedicated to quality continuing education and training programs. IACET is the only standard-setting organization approved by the American National Standards Institute (ANSI) for continuing education and training. The ANSI/IACET 1-2007 Standard is the core of thousands of educational programs worldwide. For more information, please visit www.iacet.org or call 703-506-3275.

Click here to see all recent news from this company

WINCHESTER, CA–(Marketwire – October 20, 2010) –  For many of the talented veterans participating in the National Veterans Creative Arts Festival this year in Tomah, Wisconsin, the interest in art as therapy came about during a Department of Veterans Affairs (VA) hospital stay. VA utilizes a unique rehabilitation treatment component which often includes exposing veteran patients to a variety of creative healing opportunities.

With humble beginnings in 1981 as two separate competitions: “Vet Arts” in Richmond, Virginia and “The National Music Competition for Veterans” in Waco, Texas, the annual Festival is now a popular national event showcasing the artistic achievements of veterans from across the nation. The roughly 130 veterans invited to the Festival this year are winners of fine arts and talent competitions in which thousands of veterans have entered. The event is a celebration of achievements in art, creative writing, dance, drama and original writing with a gala variety show featuring a professional orchestra.

“The National Veterans Creative Arts Festival is an exciting event. The intricate, original artwork and incredible performance talent displayed is outstanding,” said Mike Lynch, president and CEO of Help Hospitalized Veterans (HHV) an event co-sponsor. “The therapeutic benefits veterans receive from participating is highly evident. The stage show is first-class and features our nation’s top veteran performers and the craftwork displayed during the art exhibit is breathtaking,” said Lynch. The Festival takes place on Sunday, October 24, 2010 at the Viterbo University Fine Arts Center in La Crosse, Wisconsin. The art exhibit opens at 12:15 p.m. and the stage show begins at 2:00 p.m. Admission is free, but a ticket is required for the stage show.

Since 1971, HHV has donated over 28 million free arts & crafts and other products and services to VA and military hospitals worldwide. For more information visit www.hhv.org or call 1-888-567-VETS.

Documents and/or Photos available for this release:

PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 274935

PALO ALTO, CA–(Marketwire – October 20, 2010) –  

• Independent review board commends system’s design and performance
• Thirteen programs earn disease management certification status
• Company leads telehealth industry in certification 

Robert Bosch Healthcare, Inc., a leader in telehealth systems, announced today that it received recertification in Disease Management (DM) from the National Committee for Quality Assurance (NCQA) for ten of its Health Buddy^® System Health Management programs, and new certification for three additional programs. All 13 Health Management programs are administered through the Health Buddy System, which serves as an interface between at-home chronically ill patients and their care providers, facilitating remote monitoring of patient health status and promoting patient education and self-care.

“NCQA DM certification demonstrates that an organization is well suited to deliver programs to manage care for the seriously or chronically ill. As it’s a difficult test, it says a lot that an organization is willing to step forward to be reviewed,” said NCQA Executive Vice President, Greg Pawlson, M.D.

NCQA certification is a comprehensive and transparent evaluation through which the quality of the systems, processes and results that define a health plan is assessed. After evaluations are conducted by physicians and/or experts in the product evaluated, an oversight committee analyzes the findings and assigns a score based on the applicant’s performance against NCQA’s standards. Robert Bosch Healthcare received a score of 100%, based on its overall submissions. Each certification is valid for two years.

Bosch leads the industry in its number of NCQA certifications. Ten Health Buddy System Health Management Programs recertified are: Asthma, Cancer, Cardiovascular Disease, Congestive Heart Failure, Chronic Pain, Chronic Obstructive Pulmonary Disease (COPD), Depression, Diabetes, Hypertension and Pediatric Asthma. New programs receiving certification for the first time are: Diabetes/Hypertension, Heart Failure/Diabetes and Renal Disease.

These programs scored high in each element of the DM certification for Program Design. Evaluation criteria includes the use of evidence-based guidelines or standards of care in program development, consistency of content with adopted guidelines, and development of patient information that assists with self-management. NCQA noted specific strengths of the Health Buddy System: the large array of disease programs offered; the branching logic applied to the patient question and answer “dialogues”; and Bosch Healthcare’s process for tracking and changing content as guidelines change. Also noted was the use of health dialogues to gather an extensive amount of patient data, in order to identify and address patient safety issues. The risk stratification of safety alerts allows immediate review of information by a clinician.

“The rigorous, independent review taken by NCQA underlines the high quality standards and demonstrated effectiveness of the Health Buddy System in improving care for patients with chronic conditions,” said Derek Newell, President Robert Bosch Healthcare. “Each day, around 30,000 patients connect to their care providers using the Health Buddy System. Customers can be assured that our Health Management Programs are based on sound clinical principles and standard guidelines, which ultimately enable care providers to better support chronically ill patients without increasing costs.”

About the Bosch Healthcare Health Buddy System
In use for more than ten years, the Health Buddy System includes a compact device that patients use at home to answer a series of questions about their health and symptoms, and receive information that helps them better manage their chronic conditions. Patient data gathered by the device is transmitted to a secure data center and quickly risk-stratified, giving proactive providers the opportunity to intervene before the patient’s condition becomes critical. 

About the National Committee for Quality Assurance
The National Committee for Quality Assurance (NCQA) is a non-profit organization dedicated to improving health care quality. Since its founding in 1990, NCQA has been a central figure in driving improvement throughout the health care system. Through its certification review process, NCQA certifies a wide range of health care organizations and programs. Its disease management certification standards are intended to reduce patient risk, help organizations achieve the highest level of performance possible, and create an environment of continuous improvement. For more information, visit www.ncqa.org.

About The Bosch Group:

Robert Bosch Healthcare Inc. is a leading provider of innovative telehealth systems. Bosch’s product spectrum ranges from patient terminals to comprehensive evaluation software allowing healthcare professionals to efficiently evaluate the data coming from the patient terminals and other connected devices. Bosch Telehealth strives to improve diagnosis and treatment through systematic patient monitoring and involvement. The result is that health professionals are able to provide a higher quality of care for patients with chronic conditions, patients lead happier and healthier lives, and the cost of healthcare is reduced for funders. Robert Bosch Healthcare, Inc. is a fully-owned subsidiary of the Bosch Group. For more information, go to www.bosch-telehealth.com.

The Bosch Group is a leading global supplier of technology and services. In the areas of automotive and industrial technology, consumer goods, and building technology, some 275,000 associates generated sales of 38.2 billion euros (roughly $53 billion) in fiscal 2009. The Bosch group comprises Robert Bosch GmbH and its more than 300 subsidiaries and regional companies in over 60 countries. This worldwide development, manufacturing, and sales network are the foundation for growth. Each year, Bosch spends more than 3.5 billion euros ($5 billion) for research and development, and applies for some 3,800 patents worldwide. With all its products and services, Bosch works to enhance the quality of life by providing solutions which are both innovative and beneficial. For more information, visit www.bosch.com.

In the U.S., Canada and Mexico, the Bosch Group manufactures and markets automotive original equipment and aftermarket products, industrial drives and control technology, power tools, security and communication systems, packaging technology, thermotechnology, household appliances, solar energy and healthcare products. Having established a regional presence in 1906, Bosch employs over 20,000 associates in more than 70 locations, with reported sales of $7.3 billion in fiscal 2009. For more information, visit www.boschusa.com.

National Committee for Quality Assurance
Celebrating its 20th anniversary in 2010, NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care. NCQA is committed to providing health care quality information for consumers, purchasers, health care providers, and researchers. 

Click here to see all recent news from this company

WOOD DALE, IL–(Marketwire – October 20, 2010) –  SANYO North America Corporation (SANYO) announces that its Biomedical Solutions Division is moving to the forefront of the stem cell and cell therapy market with the introduction of the industry’s first integrated, stand-alone Cell Processing Work Station (CPWS), becoming a significant solutions provider in this high growth, high opportunity marketplace. Offering a turnkey and standalone solution, SANYO’s CPWS is an innovative, cost effective and space-saving solution for the GMP compliant processing and manufacture of regenerative stem cell and cell therapies. The CPWS lowers barriers to enter the cell therapeutics market, positively impacting both public and private institutions. The workstation provides the required class-100 aseptic environment, but in a compact and less expensive than a traditional costly and large footprint cleanroom.

The cell therapy market is increasingly playing an important role in the practice of medicine, and the number of companies and entities that are involved in cell therapy are on the rise, including academic institutions and public and private companies. The market is expected to expand over the next decade, with applications for the technology to include cancer, cardiac and genetic disorders as well as wounds of the skin and soft tissues.

“SANYO is prepared to expand into this rapidly growing market with its new Cell Processing Work Station, which will provide a practical solution for its biotech and pharmaceutical customers to develop and manufacture advanced cell therapies and hospitals to develop cell therapies for use in clinical trials,” stated Ron Dudek, New Business Development Manager.

The CPWS is a stand-alone, alternative to a traditional cleanroom, and the station is a self-contained system with a small footprint that is quick and easy to install. Offering a highly efficient operational capacity and featuring a contamination-free design, the workstation includes cGMP compliant equipment for aseptic processing and provides user-friendly operation. The SANYO CPWS also saves approximately 35% of the operating costs usually required for conventional cleanrooms (open systems).

The CPWS significantly lowers barriers to entry to the cell therapeutics market, which will impact both the private and public institutions within the life science, clinical, biotechnology and pharmaceutical markets. Current and future applications of the CPWS include regenerative organ development, and tissue regeneration such as skin, cartilage, alveolar bone, cornea, cardiac muscle, nerve, liver and pancreas.

Main Features of the CPWS
Self-Contained System, Small Footprint
The small footprint permits installation into existing or new lab spaces using conventional utilities and minimal site preparation. The CPWS individual docking incubators reduce product mix-up and cross-contamination errors. An optional built-in centrifuge and cell observation microscope/monitor further reduce laboratory space requirements as well as improve aseptic processing.

Higher Efficiency
By using a highly effective H₂ O₂ decontamination process, the CPWS can be completely sterilized without heat and prepared for the next protocol within two hours instead of the conventional cleanroom decontamination protocol that can take days or weeks.

Contamination-free Design
The four-port glove box delivers more than a conventional Class II, Type A2 biological safety cabinet typically installed within a cleanroom to achieve the same level of contamination or cross-contamination prevention. Centrifuge and incubator access from within the Class 100 work station environment enhances aseptic processing.

Other Key Features

• Approximately 35% less expensive to operate than a conventional cleanroom (open system).
• The barrier isolator creates a grade A or class 100 environment within the workstation (When installed in a class 100,000 cleanroom).
• Gowning is not required, allowing for a significant improvement in user comfort and productivity upon entrance and exit from the aseptic environment.

About SANYO
SANYO Electric Co., Ltd. is a global, leading provider of energy, environment, and lifestyle applications. Biomedical Solutions, a Division of SANYO North America Corporation (a subsidiary of SANYO Electric Co., Ltd.), is based in Wood Dale, IL, and provides laboratory equipment for pharmaceutical, life science and biotechnology applications. Product lines include space-efficient VIP^® ultra-low temperature freezers, cryogenic freezers, pharmaceutical and medical refrigerators, cell culture incubators, plant growth chambers, and portable autoclaves.
To learn more about SANYO, please visit http://us.sanyo.com

id=”nav_links”>

WESTPORT, CT–(Marketwire – October 20, 2010) –  The Patient Channel, the largest U.S. hospital-based health and wellness TV channel, and dLife, the only multi-media network serving the diabetes community, have announced a strategic partnership that will significantly increase year-round diabetes education, wellness, and lifestyle programming for patients and caregivers in over 1,600 hospitals across the U.S. The partnership will help diabetes educators and patients by providing vital information at a critical time of need increase awareness and self-management, help decrease future hospital visits and encourage ongoing engagement at home.

As part of the agreement, 14 hours of dLifeTV‘s diabetes lifestyle programming will be added to The Patient Channel’s existing diabetes line-up. The partnership will begin in the fourth quarter of 2010 and advertisers will be offered special tie-in opportunities to commemorate American Diabetes Month in November. The Patient Channel’s existing topics of diabetes prevention, treatments, and avoiding complications will be supplemented with dLifeTV episodes profiling real people overcoming the challenges of living with diabetes, as well as interviews with celebrities living with diabetes such as The View co-host, Sherri Shepherd, and CBS newsman, Bob Schieffer. There will also be special programming on topics as varied as religion and diabetes, diabetes in the workplace, and the latest diabetes gadgets.

Patients will be encouraged to watch dLifeTV (Sundays at 7 p.m. ET, 4 p.m. PT on CNBC), as well as join dLife’s award-winning website, dLife.com, which has over one million visitors each month.

“Diabetes diagnosis often happens in the hospital, and inpatient stays are often caused by diabetes and its complications. For many of them it can be a time of profound fear, confusion and isolation. Not to mention a supreme teachable moment to improve their diabetes IQ going forward. We are delighted by our new partnership with The Patient Channel, which allows us to put dLifeTV in front of people with diabetes at such a critical time of need,” says Howard Steinberg, CEO and founder of dLife.

“The Patient Channel hospital footprint reaches 35 percent of hospitalized Americans with or at risk for diabetes,” says Dave Ross, COO of The Patient Channel. “This programming will help hospitals and diabetes educators to educate and improve the compliance of patients and families at the very time they are motivated and seeking information to manage their condition and lifestyle.” 

For a full list of the diabetes programming running on The Patient Channel, as well as other details about The Patient Channel’s educational offering and platform, visit www.thepatientchannel.com.

For additional resources on managing your or your patients’ diabetes lifestyle, please go to www.dLife.com.

About Interactivation Health Networks
The Patient Channel and the Newborn Channel are the most comprehensive in-hospital TV networks. Delivered directly to patient rooms and waiting areas, the Channels provide viewers with original, award-winning health programs and advertisers with the unique ability to integrate brand messaging with content that is compelling and endorsed by healthcare professionals. The Newborn Channel broadcasts baby care and postpartum programming for new parents, reaching 60% of new moms. The Patient Channel features both condition-specific and preventative health programming to empower and inform patients. The channels are currently available in over 2,700 hospitals nationwide. For more information, visit www.thenewbornchannel.com and www.thepatientchannel.com

About dLife – For Your Diabetes Life
dLife is the only multimedia network serving the diabetes community. Its award-winning media outlets include dLife.com, the leading online destination for diabetes information, inspiration, and connection, featuring more than 9,000 recipes, 400 videos, and 80,000 pages of content; dLifeTV, the only lifestyle TV series for people with diabetes, airing every Sunday on CNBC (7 p.m. ET, 4 p.m. PT); and other consumer and professional programs to inform, inspire and connect people with diabetes and those who care for them every day.

MCLEAN, VA–(Marketwire – October 20, 2010) – Patient payments are an increasing and critical part of the overall revenue stream for today’s healthcare providers. With approximately 50% of patient payments being written off as bad debt; point-of-care payments solutions help ensure payment is both received and approved. Sage Payment Solutions, the payments division for Sage North America, today announced the launch of Sage Patient Payments, a secure payment solution that enables collections from patients at the point of care, regardless of the patient’s third-party payer.

“With co-pays, deductibles, and the balance not covered by the patient’s insurance provider, healthcare payments have been historically challenging for patients to figure out,” said Greg Hammermaster, president of Sage Payment Solutions. “This confusion results in doctors’ offices focusing more on billing, payment, and collections, which drives up their costs. Sage Patient Payments streamlines the payment process facilitating accurate and timely payment to the doctors’ office while mitigating the patients’ confusion.”

By the end of this year, about 35% of a provider’s total revenue will derive directly from patient payments, according to the McKinsey & Co. report, “Overhauling the US Health Care Payment System.” Sage Patient Payments provides everything needed to handle patient payments at the point of care. The product’s calculator instantly determines the estimated service charges for a patient, taking into consideration relevant health plan discount arrangements.

Powered by mPay Gateway, a leading developer of Payment Card Industry (PCI) certified financial technology products and services for the healthcare industry, Sage Patient Payments provides patients with a simpler, easier-to-understand billing process. Physicians can dramatically reduce their receivables, bad debt, and patient statement costs in three easy steps.

After reviewing a summary of charges with a patient, healthcare providers can swipe the patient’s credit or debit card and obtain the patient’s commitment to pay up to that amount. These steps allow healthcare providers to directly collect the exact amount owed at a later date, after the patient’s insurance company or other third-party payer determines what the patient owes. The patient is never charged more than the estimate, and the provider never needs to send another bill.

Other features of Sage Patient Payments tailored to the unique healthcare environment include: payment plans, health benefit plan eligibility lookup, and a check and cash log to track all patient payments.

In addition to Sage Patient Payments, Sage offers numerous products and services used by the healthcare industry, including Sage Intergy for practice management, Sage Intergy EHR for electronic health records, and Sage Transaction Services for electronic data interchange (EDI). Approximately 80,000 physicians and thousands of ambulatory care practices throughout North America use Sage software and services to better manage their practices and improve profitability.

For more information on Sage Patient Payments or other products and services from Sage Payment Solutions, please visit www.sagepayments.com or call 800-261-0240.

About Sage Payment Solutions
Sage Payment Solutions, the payments division for Sage North America, has been providing businesses and organizations with electronic payment systems for more than 20 years. The company makes electronic payment processing easy for more than 155,000 merchants, allowing them to accept multiple forms of payment, including credit and debit cards, electronic checks, Check21, gift and loyalty cards, and automatic recurring payment. Sage Payment Solutions provides a wide range of secure standalone and integrated payment processing solutions. Sage Exchange, its PA-DSS certified payments platform, integrates with many Sage software products to maximize the value of customers’ business systems with automatically updated credit and debit card transaction information. Future Sage Exchange releases will offer additional integrated payment capabilities, including advanced point-of-sale (POS) device integration, payment origination solutions, and cash management applications. For more information about Sage Payment Solutions, please call 800-261-0240, or visit www.sagepayments.com.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.